Skip to main content
Defiance International

Published study records

Study records.

Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.

Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.

Study record counts

68,366 study records.

407 evidence-verified · 10,493 citation-verified · 57,416 identifier-confirmed · 50 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • Human research: 689
  • In vitro: 2,868
  • In vivo/preclinical: 3,719
  • Review/meta-analysis: 3,624
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2015

Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.

Drug design, development and therapy · 2015

Study scale: Male Sprague Dawley rats (n=58) weighing 160 g–220 g were chosen for the experiments.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The present study aimed to investigate the wound healing effects of synthesized BPC-157 on alkali-burned rats and elucidate its mechanisms of action.

Study design

Not reported in the declared source.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Male Sprague Dawley rats (n=58) weighing 160 g–220 g were chosen for the experiments.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

To assess the influence of BPC-157 on cell growth, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay was used.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2015

Electrophysiological Studies into the Safety of the Anti-diarrheal Drug Clotrimazole during Oral Rehydration Therapy.

PLoS neglected tropical diseases · 2015

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Jejunal tissue preparations were apically and basolaterally treated with 5, 30, and 150 μM clotrimazole (CLT) or vehicle control for 20 minutes in Ussing chambers and subsequently challenged with the cAMP-dependent secretagogue VIP (7.5 nm) or the Ca2+-dependent secretagogue carbachol (20 μM).

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2015

Periosteum Metabolism and Nerve Fiber Positioning Depend on Interactions between Osteoblasts and Peripheral Innervation in Rat Mandible.

PloS one · 2015

Study scale: Forty 8 weeks-old rats were distributed at random in two lots.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

To this goal, VIP content and/or activity were modulated in vivo and the impact on osteoblast activity and expression of NGF and sema3a was determined.

Participants or experimental system

Eight weeks-old male Wistar rats (Iffa Credo, L’Arbresle, France), weighing 250 ± 20 g, fed a standard rodent diet (M25 Extralabo; UAR, Villemoisson, France) were used.

Study scale

Forty 8 weeks-old rats were distributed at random in two lots.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Twenty rats were sham-treated with daily saline ip injections and used as controls.

Outcomes examined

In the non-osteogenic compartment, we quantified (a) the number of ßNGF+ mast cells (N/mm of adjacent bone surface).

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

While these data show that the cholinergic innervation significantly impacts osteoblastic cell behavior, how these cells act on the fibers innervating the periosteum remains unknown.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2015

The neurochemistry and social flow of singing: bonding and oxytocin

Frontiers in Human Neuroscience · 2015

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

As a feasibility study, a primary purpose was to evaluate the design and methodology.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2014

Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.

PloS one · 2014

Study scale: A total of six mice were studied in each group.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The purpose of this study is to evaluate the whether Tβ4 can be used as a vascular-protective agent.

Study design

To corroborate the in vivo studies, we performed our analysis using lung microvascular endothelial cells (MVEC) stimulated with TGFβ1.

Participants or experimental system

Twelve-week-old male mice (∼25 g) were used for experiments.

Study scale

A total of six mice were studied in each group.

Intervention or exposure

Briefly, wild-type (WT) mice received an intraperitoneal (i.p) injection of MCT (80 mg/kg body wt) every 20 days for 3 times.

Comparator

Age- and sex-matched WT with normal saline-injected mice of C57BL/6 background served as controls.

Outcomes examined

The pathogenesis of MCT-induced PH was evaluated through RV pressure measurement.

Key findings

In monocrotaline (MCT)-induced PH mouse model, we showed that mice treated with Tβ4 significantly attenuated the systolic pressure and RVH, compared to the MCT treated mice.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2014

CerebrolysinTM efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.

BMC neuroscience · 2014

Study scale: A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy.

Study design

Not reported in the declared source.

Participants or experimental system

Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically.

Study scale

A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.

Intervention or exposure

Animals were treated beginning at 3 months of age for 3 months, because at the earlier age group the Tau pathology was subtler, becoming progressively worse at 6 and 12 months of age.

Comparator

By immunoblot, levels of t-Tau were elevated in the Tau/GSK3β bigenic mice compared to the non-tg, no effects of CBL administration on t-Tau were observed (Figure 3A-D).

Outcomes examined

Non-tg and bigenic mice were treated for 3 months (beginning at 3 months of age) with CBL and brains were analyzed with p-tau antibodies.

Key findings

CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2014

Autism, oxytocin and interoception

Neuroscience and biobehavioral reviews · 2014

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not reported in the declared source.

Participants or experimental system

Not reported in the declared source.

Study scale

Not reported in the declared source.

Intervention or exposure

Not reported in the declared source.

Comparator

Not reported in the declared source.

Outcomes examined

Not reported in the declared source.

Key findings

Oxytocin may thus play a role similar to other modulators of NMDA receptor function, in mediating top down modulation, not only in the cortex, but also in the autonomic nervous system and associated subcortical regions of the brain.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2014

Antiapoptotic factor humanin is expressed in normal and tumoral pituitary cells and protects them from TNF-α-induced apoptosis.

PloS one · 2014

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

We also evaluated HN action on the proapoptotic effect of TNF-α in anterior pituitary cells assessed by the TUNEL method.

Study design

Not reported in the declared source.

Participants or experimental system

Adult Wistar female and male rats were kept in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Study scale

Not reported in the declared source.

Intervention or exposure

Sliced fragments were dispersed enzymatically by successive incubations in DMEM-S-BSA, containing 0.75% trypsin, 10% fetal bovine serum (FBS) previously treated with 0.025% dextran-0.25% charcoal (FBS-DCC) to remove steroids and 45 U/µl deoxyribonuclease type I (Invitrogen).

Comparator

Rats were ovariectomized (OVX), orquidectomized (GNX) or sham-operated two weeks before experiments.

Outcomes examined

The presence of HNr in pituitary sections and dispersed anterior pituitary cells was evaluated by indirect immunofluorescent staining.

Key findings

In the present work, we demonstrated by immunocytochemical analysis and flow cytometry the expression of HNr in the anterior pituitary of female and male adult rats as well as in pituitary tumor GH3 cells.

Limitations and uncertainty

The mechanism by which HN protects anterior pituitary cells from proapoptotic stimuli, not examined in the present study, remains to be determined.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2013

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.

Critical care (London, England) · 2013

Study scale: A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

The trial is to evaluate whether Tα1 improves 28-day all-cause mortality rates and immunofunction in patients with severe sepsis.

Study design

We performed a multicenter randomized controlled trial in six tertiary, teaching hospitals in China between May 12, 2008 and Dec 22, 2010.

Participants or experimental system

Eligible patients admitted in ICU with severe sepsis were randomly allocated by a central randomization center to the control group or Tα1 group (1:1 ratio).

Study scale

A total of 361 patients were allocated to either the control group (n = 180) or Tα1 (n = 181) group.

Intervention or exposure

In the Tα1 group, patients received subcutaneous injections of 1.6 mg Tα1 (ZADAXIN™, SciClone Pharmaceuticals, Foster City, CA, USA) twice per day for five consecutive days, then once per day for two consecutive days.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

The primary outcome was death from any cause and was assessed 28 days after enrollment.

Key findings

Greater improvement of mHLA-DR was observed in the Tα1 group on day 3 (mean difference in mHLA-DR changes between the two groups was 3.9%, 95% CI 0.2 to 7.6%, P = 0.037) and day 7 (mean difference in mHLA-DR changes between the two groups was 5.8%, 95% CI 1.0 to 10.5%, P = 0.017) than in the control group.

Limitations and uncertainty

In our study, several factors limit the extent to which the results can be generalized.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2013

A Gq-Ca2+ axis controls circuit-level encoding of circadian time in the suprachiasmatic nucleus.

Neuron · 2013

Study scale: One week after transduction, strong signal was evident in neurons across the SCN and overall fluorescence was highly circadian, with estimated [Ca2+]i ranging between 113 ± 7.5nM (nadir) and 191 ± 25nM (zenith, mean ± SEM n = 3, see Experimental Procedures; Figure 4A; Movie S2).

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Having characterized this program, and shown its dependence upon neuropeptidergic G-coupled signaling, we then sought to examine causal relationships within it.

Study design

Not reported in the declared source.

Participants or experimental system

VIP-IRESCre (Viptm1(cre)Zjh/J) and R26 floxed STOP EYFP (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA).

Study scale

One week after transduction, strong signal was evident in neurons across the SCN and overall fluorescence was highly circadian, with estimated [Ca2+]i ranging between 113 ± 7.5nM (nadir) and 191 ± 25nM (zenith, mean ± SEM n = 3, see Experimental Procedures; Figure 4A; Movie S2).

Intervention or exposure

Not reported in the declared source.

Comparator

Vehicle treated SCN received ddH2O as vehicle treatment.

Outcomes examined

To test this, the spatiotemporal dynamics of Per2:luc and Cry1-luc expression were analyzed.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2013

Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

PloS one · 2013

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

In the present study, we aimed to evaluate the vasodilatory potential of the synthetic, stable VIP analog RO 25-1553 in the pulmonary circulation.

Study design

In a second set of experiments, we tested whether RO 25-1553 exerts a similar vasodilatory effect in the pulmonary vasculature when a) administered by inhalation and b) in an in vivo setting rather than an isolated organ preparation.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not reported in the declared source.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2012

Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans.

PloS one · 2012

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Plaque specimens from 34 patients undergoing carotid endarterectomy were classified according to symptomatic history.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not reported in the declared source.

Key findings

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked